Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP. Giulino-Roth L, et al. Br J Haematol. 2017 Dec;179(5):739-747. doi: 10.1111/bjh.14951. Epub 2017 Oct 29. Br J Haematol. 2017. PMID: 29082519 Free PMC article.
Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia.
Mo G, Wang HW, Talleur AC, Shahani SA, Yates B, Shalabi H, Douvas MG, Calvo KR, Shern JF, Chaganti S, Patrick K, Song Y, Fry TJ, Wu X, Triplett BM, Khan J, Gardner RA, Shah NN. Mo G, et al. Among authors: gardner ra. J Immunother Cancer. 2020 Nov;8(2):e001563. doi: 10.1136/jitc-2020-001563. J Immunother Cancer. 2020. PMID: 33246985 Free PMC article.
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah NN. Myers RM, et al. Among authors: gardner ra. J Clin Oncol. 2022 Mar 20;40(9):932-944. doi: 10.1200/JCO.21.01405. Epub 2021 Nov 12. J Clin Oncol. 2022. PMID: 34767461 Free PMC article.
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.
Hsieh EM, Myers RM, Yates B, Annesley C, John S, Taraseviciute A, Steinberg SM, Sheppard J, Chung P, Chen L, Lee DW, DiNofia A, Grupp SA, Verneris MR, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Gore L, Shah NN, Lamble AJ. Hsieh EM, et al. Among authors: gardner ra. Blood Adv. 2022 Sep 13;6(17):5222-5226. doi: 10.1182/bloodadvances.2022008093. Blood Adv. 2022. PMID: 35834728 Free PMC article. No abstract available.
186 results